Showing 461 - 480 results of 5,248 for search '"Vascular endothelial growth factor"', query time: 0.22s Refine Results
  1. 461
  2. 462

    Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry by Gonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, Hemal Mehta, Alessandro Invernizzi, Pierre-Henry Gabrielle, Tremeur Guillaumie, Benjamin Wolff, Mark C. Gillies, Javier Zarranz-Ventura

    Published 2024-03-01
    “…Abstract To compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor (anti-VEGF) we performed a multi-centre, retrospective and observational study using Fight Retinal Blindness! …”
    Get full text
    Article
  3. 463

    Vascular endothelial growth factor a modified mRNA engineered cellular electrospun membrane complexes promotes mouse skin wound repair by Xuefeng Ai, Runjiao Luo, Huijing Wang, Bingqian Yan, Kaixiang Li, Xindi Yu, Wei Dong, Yao Tan, Minglu Liu, Ying Chen, Tingting Lu, Xiangying Wang, Wei Wang, Wei Fu

    Published 2023-10-01
    “…Early angiogenesis is essential for wound healing and graft survival and vascular endothelial growth factor A (VEGFA) is an important cytokine that stimulates angiogenesis. …”
    Get full text
    Article
  4. 464
  5. 465
  6. 466
  7. 467

    Correlation between vascular endothelial growth factor A gene polymorphisms and tendon and ligament injury risk: a systematic review and meta-analysis by Xi-yong Li, Yun-lu Wang, Su Yang, Chang-sheng Liao, Song-feng Li, Peng-fei Han

    Published 2024-02-01
    “…Abstract Background Relevant evidence suggests that angiogenic factors contribute significantly to fibril matrix reconstruction following physical injuries to tendon ligaments. Vascular endothelial growth factor A (VEGFA), with its potent angiogenic effect, has been studied extensively, and its functional polymorphisms, including rs699947, rs1570360, and rs2010963, have been the focus of numerous investigations. …”
    Get full text
    Article
  8. 468

    Evaluation of Cyclooxygenase-2, P53, Vascular Endothelial Growth Factor, and Nitric Oxide Synthase-2 in Angiogenesis and Growth of Tobacco-Related Malignancies by Shruti Gautam, Manisha Sangma, Safia Rana, Shaan Khetrapal, Sujala Kapur, Zeeba S. Jairajpuri

    “…The present study focuses on the expression of cyclooxygenase-2 (COX-2), P53, vascular endothelial growth factor (VEGF), and nitric oxide synthase (NOS) and their relationship with the growth and angiogenesis of tobacco-related malignancies of the oral cavity, esophagus, lungs, and stomach. …”
    Get full text
    Article
  9. 469
  10. 470
  11. 471
  12. 472
  13. 473

    Ultra-Wide-Field Fluorescein Angiography Assessment of Non-Perfusion in Patients with Diabetic Retinopathy Treated with Anti-Vascular Endothelial Growth Factor Therapy by Jean-Baptiste Morel, Franck Fajnkuchen, Fatima Amari, Nanthara Sritharan, Coralie Bloch-Queyrat, Audrey Giocanti-Aurégan

    Published 2023-02-01
    “…<b>Purpose</b>: To follow the evolution of peripheral ischemia by fluorescein angiography (FA) on ultra-wide-field (UWF) images in diabetic patients treated with anti-vascular endothelial growth factor (anti-VEGF) for macular edema. …”
    Get full text
    Article
  14. 474
  15. 475
  16. 476

    Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. by Ze-Feng Zhang, Tao Wang, Li-Hua Liu, Hui-Qin Guo

    Published 2014-01-01
    “…BACKGROUND: Vascular endothelial growth factor tyrosine-kinase inhibitors (VEGFR-TKIs) have emerged as an effective targeted therapy in the treatment of cancer patients, the overall incidence and risk of proteinuria associated these drugs is unclear. …”
    Get full text
    Article
  17. 477

    Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion by Yoo-Ri Chung, Tae Kyoung Woo, Ha Ryung Park, Kihwang Lee

    Published 2023-07-01
    “…Abstract We investigated the efficacy of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in branch retinal vein occlusion (BRVO). …”
    Get full text
    Article
  18. 478
  19. 479

    Relationship between serum fibroblast growth factor 19 and vascular endothelial growth factor and soluble klotho protein in type 1 diabetic children by Yanjun Zhang, Guimei Li, Feifei Xiao, Bang Wang, Jianchang Li, Xiuhong Jia, Yan Sun, Hongye Chen

    Published 2023-03-01
    “…This study aimed at at evaluating the relationship among the levels of serum FGF19 and vascular endothelial growth factor(VEGF)and soluble klotho protein(sklotho) in type 1 diabetic children. …”
    Get full text
    Article
  20. 480